Abstract: This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula:
in which A is a moiety of the formula
where
the dotted line represents optional unsaturation;
R1 is hydrogen or alkyl;
R2 is alkyl;
R4 is hydrogen, alkyl, formyl, or alkanol;
R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;
R7 is hydrogen or alkyl; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 30, 2001
Date of Patent:
April 29, 2003
Assignee:
Wyeth
Inventors:
Richard L. Rudolph, Albert T. Derivan, G. Virginia Upton
Abstract: The present invention relates to topical compositions for effecting an immediate improvement in the appearance and feel of skin, in addition to providing chronic improvements in skin appearance. The compositions comprise from 0.5% to 25% of a first particulate material having a refractive index of from 1.3 to 1.7, the particulate material being dispersed in the composition and having a median particle size of from 2 to 30 um, and an active effective for chronically regulating skin condition selected from Vitamin B3 compounds, retinoids, and mixtures thereof. Preferred emobodiments are oil in water emulsions further comprising a second particulate material having a larger particle size than the first.
Type:
Grant
Filed:
November 8, 2001
Date of Patent:
April 22, 2003
Assignee:
The Procter & Gamble Company
Inventors:
Petra Helga Beck, Robert Francis Date, Mario Elmen Tremblay
Abstract: A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF gene, e.g., cystic fibrosis, or a chronic inflammatory disorder, e.g., ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.
Type:
Grant
Filed:
November 3, 2000
Date of Patent:
April 22, 2003
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: Disclosed is a method of treating an individual or animal with osteoarthritis. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor.
Type:
Grant
Filed:
March 10, 1998
Date of Patent:
April 22, 2003
Inventors:
Thomas R. Sharpe, George W. Vasios, R. Nelson Campbell
Abstract: Disclosed herein are methods for treating immune-mediated ear disorders, such as IMCVDs, or their symptoms, involving administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide.
Type:
Grant
Filed:
March 27, 2001
Date of Patent:
April 15, 2003
Assignee:
The General Hospital Corporation
Inventors:
Mahboob U. Rahman, Dennis S. Poe, Hyon K. Choi
Abstract: An effervescent sub-lingual type composition, optionally in tablet form, comprising at least one active ingredient, one ore more fruit acids, and one or more effervescing alkalis, wherein at least the acid component(s) have been coated with protective layer of polydimethylsiloxane that substantially minimizes contact between the acid(s) and atmospheric moisture until the composition is purposely mixed with water or is used sub-lingually. A method of preparation of the effervescent compositions is also dislcosed.
Abstract: A composition containing a cooling-sensation imparting substance and a cationic surfactant results in an excellent cooling sensation effect. A composition additionally containing vanilylalkyl ether, wherein the alkyl group has 1 to 6 carbon atoms, is also effective as a composition for improving cooling sensation effect. The present composition for improving cooling sensation effect improves cooling sensation effect while also sustaining that effect. In particular, the present invention provides a composition for improving cooling sensation effect that is able to impart a cooling sensation effect and sustain that effect when used after washing the hair using a shampoo containing no cooling sensation substance or a shampoo containing only a small amount of cooling sensation substance.
Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Type:
Grant
Filed:
January 8, 2001
Date of Patent:
April 8, 2003
Assignee:
Merck & Co., Inc.
Inventors:
Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
Abstract: A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula
wherein
R1 and R3 are independently hydrogen,
wherein Ar is optionally substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 8, 2003
Assignee:
Eli Lilly and Company
Inventors:
David T. Berg, David S. Calnek, Brian W. Grinnell
Abstract: The present invention provides methods of modulating or inhibiting microglia activation comprising the administration of a compound capable of inhibiting 5-LOX, FLAP, attenuating degradation of I&kgr;B&agr; or inhibiting nuclear translocation of the NF-&kgr;B active complex for the treatment of Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain.
Type:
Grant
Filed:
July 5, 2001
Date of Patent:
April 8, 2003
Assignee:
Bristol-Myers Squibb Company
Inventors:
Rand M. Posmantur, Lav Kumar Parvathenani
Abstract: The invention relates to the use of direct or indirect selective inhibitors of factor Xa acting via antithrombin III, alone or in combination with one or more compounds with anti-platelet aggregation activity, for the preparation of medicines intended to prevent and to treat thromboembolic arterial diseases.
The subject of the invention is also pharmaceutical compositions containing one or more direct or indirect selective inhibitors of factor Xa which act via antithrombin III in combination with one or more compounds with anti-platelet aggregation activity, and optionally one or more pharmaceutically acceptable vehicles.
Abstract: Compositions that are selective PDE III inhibitors and that are effective to treat sexual dysfunction in males and females, including, but not limited to, erectile dysfunction in males. The compositions comprise halogenated quinolines, isoquinolines, quinolones, thioquinolones and 2-oxoquinolones, including derivatives thereof. The compounds can be taken orally or by a number of different routes or can be used to coat the interior of a condom to induce erection.
Abstract: The present invention is a method of treating an mammal selected from the group consisting of humans and horses who has asthma, COPD or allergic rhinitis and is in need of such treatment by inhaling an anti-asthma, anti-COPD anti-allergic rhinitis effective amount, respectively, of a compound selected from the group consisting of tolterodine
hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
October 23, 2001
Date of Patent:
March 25, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Per-Goran Gillberg, Staffan Sundquist, Sue K. Cammarata
Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.
Type:
Grant
Filed:
February 23, 1998
Date of Patent:
March 25, 2003
Assignee:
Bone Care International, Inc.
Inventors:
Charles W. Bishop, Joyce C. Knutson, Richard B. Mazess
Abstract: An anesthetic is provided that includes a mixture of propofol, a tonicity agent, a substantially phospholipid-free emulsifying agent, a preservative such as benzyl alcohol, and water. This anesthetic is made by combining these components and then filtering the mixture of these components through a sterilizing filter. This anesthetic may be parenterally administered to both induce and maintain anesthesia in animals.
Abstract: An aqueous gel in unit dose form and suitable for topical delivery of clonidine and comprising clonidine, a water-gelling amount of a pharmaceutically acceptable gelling agent and having a pH value in the range of about 6 to about 8.5. Clonidine is present in an amount in the range of about 0.05 to about 3.5 milligrams per unit dose and at a concentration in the range of about 0.01 to about 0.5 weight percent.
Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).
Type:
Grant
Filed:
March 7, 2001
Date of Patent:
March 18, 2003
Assignees:
Allos Therapeutics, Inc., Virginia Commonwealth University
Inventors:
Donald J. Abraham, Changging Wang, Richmond Danso-Danquah, James C. Burnett, Gajanan S. Joshi, Stephen J. Hoffman
Abstract: Compositions useful in relieving craving in nicotine habituated patients are provided that include an herbal component. The herbal component provides multiple nicotine agonists, one of which is anabasine. The compositions are preferably in the form of chewing gum, tablets, capsules, or lozenge.
Type:
Grant
Filed:
June 4, 2001
Date of Patent:
March 18, 2003
Assignee:
Phytos, Inc.
Inventors:
Philip Wolfson, Payton Jacobs, III, Alexander T. Shulgin
Abstract: An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection, rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation, or allergic disease, by selectively inhibiting the activated T cells, is provided.